The blood cancer drugs market continues to evolve rapidly as advancements in oncology research, targeted therapies, and immunotherapy reshape treatment approaches worldwide. Blood cancers—including leukemia, lymphoma, and myeloma—remain among the most diagnosed and complex cancer types, requiring continuous innovation in drug development. Pharmaceutical companies are increasingly...